Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
patentminer,
I have a copy that I purchased the minute he made it available. I would highly advise anyone with an investment in Marathon to consider the same.
It is extremely well done and thorough, well beyond what any analyst has authored to date. Money very well spent to say the least and a nominal price relative to the value.
Out of respect for him, this clearly took a lot of time and effort to compose, I am not going to post any details from it until he makes it public himself.
Suffice it to say, it reaffirms my already strong convictions regarding my investment in the company.
The S1 they filed with the SEC indicates 38.7% beneficial ownership I believe.
Here is a link to all of their public filings in case you need to reference it.
http://www.nasdaq.com/symbol/mdvxu/sec-filings
Initial public offering of 1,391,305 units, each unit consisting of one share of common stock and one Series A Warrant, at a price to the public of $5.75 per unit.
Today they announced "it has issued today an additional 208,695 of the Company's units, pursuant to the exercise in full of the underwriters' over-allotment option granted by the Company in connection with its initial public offering completed in December."
Medovex Corp. Announces Closing of Over-Allotment Option
ATLANTA, GA--(Marketwired - Jan 16, 2015) - Medovex Corp. (NASDAQ: MDVXU), a developer of medical technology products including the DenerveX device, announced it has issued today an additional 208,695 of the Company's units, pursuant to the exercise in full of the underwriters' over-allotment option granted by the Company in connection with its initial public offering completed in December. Each unit consists of one share of common stock and one Series A Warrant at a price to the public of $5.75 per unit. The Company's units began trading on The NASDAQ Capital Market on December 19, 2014 under the ticker symbol "MDVXU". The units are expected to begin trading as separate common stock (MDVX) and warrants (MDVXW) on February 2, 2015. The gross proceeds from the initial public offering, including the over-allotment option, total $9,200,000.
Laidlaw & Company (UK) Ltd. acted as sole book-running manager.
About Medovex:
Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com
Safe Harbor Statement
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
usedtotrade,
Appreciate your thoughts. While much of this is speculation as to what the future could hold, what is interesting to note is that if they eventually did reach those type of revenues as you mention, they would literally be dropping 40-50% of it straight to the bottom line.
The low opex and huge earnings leverage is the key, I've never seen a company better able to deliver huge eps growth upon success.
Croxall mentioned this before, they can aggressively scale their business absent any real material change in their SG&A. Maybe they add an additional accountant or admin person, but their employee count will stay relatively consistent even as they scale to higher revenues.
In addition, I still believe lots of valuable assets are going to find their ways to those companies who are left standing in the space, Marathon being one of few.
I think Croxall's goal, along with Spangenberg, is to build the most dominant company in the space. Based on progress to date, I won't be surprised in the least if and when they do precisely that.
It's interesting you mention the longer term potential of cash dividends.
In light of Croxall and others considerable personal holdings, it seems natural that it would be a goal of theirs considering they personally would serve to benefit the most from such an initiative.
Said it once, say it again. Management and all of us shareholders goals are completely aligned.
Hispeed,
Appreciate you sharing your thoughts and responding. I always value your commentary.
Thanks for the affirmation and additional info. The fact that he has never been on a public board to me is very telling.
He clearly has all the money he will ever need and certainly doesn't need the resume builder. His reputation is pretty priceless in itself.
While I would never put words in anyone's mouth, one may only assume he must really believe in Medovex and what it's future could hold.
Makes me confident in also being a shareholder along with him.
I've said the same thing. It would have long been easier to just walk away from the company, the public shell, the liabilities, the negative perception and all of the disenfranchised shareholders. His own best interest would have been to simply started fresh and cleaned the slate. Most would have done precisely that, he chose not to.
It is completely counter intuitive and nonsensical to imagine the company's largest shareholder doing anything that would undermine the value of his very own large equity holding in the company.
It's hard to imagine another company whose CEO has as much skin in the game and more of a vested interest to try and drive shareholder value than this one. The CEO's upside is completely aligned with all of ours as shareholders.
So isn't much of the entire market lately my friend. We're certainly not alone.
I'm not saying I'm impressed by anything mick. I am keenly aware of the past. Trust me, it cost me more than it has cost you.
I was merely pointing out the disparity between what some have recently said and what has been proven to be the case.
Frankly I agree with what Hollis said on the recent call. All that matters is revenues and that's up to him to generate. Just like yourself, I wouldn't bet the farm on it by any means based on history, but the truth is they do appear to now have a product and there is a market opportunity for it. Like I said earlier, this is probably the lowest cost, highest margin, and most scalable opportunity they've ever had.
The truth is they have more of a real tangible business opportunity now than when the stock previously traded much higher.
We'll see what happens. The recent presentations are simply put, a small step in the right direction, yes for a change. That said, they aren't going to win back confidence overnight nor should they and they will have to perform. If they do, the stock goes higher most likely. If not, well then you're risking $.0002.
There's no doubt that Hollis has just enough rope to hang himself and he had two chances to do just that recently based on things he stated would be forthcoming. In those couple of cases, he pretty much did what he said he would. It's a start...nothing more, nothing less. Appreciate your thoughts.
That defies reason since it is he who is the largest shareholder. To say he doesn't care about shareholders would imply he doesn't care about himself. Based o your comments, you seem to indicate he cares about himself a great deal.
I'm sorry for what happened in the past but all who have ever succeeded have generally also had many failures. Show me a successful business man or entrepreneur who was only ever successful and I'll show you a person who never took a risk or was extremely lucky.
While your entitled to any opinion you like regarding management, The recent results speak for themselves. Based solely on the company's publicly filed financials, the company can only be considered very undervalued. I'd assume the results are what drove the shares to a recent new high.
In addition, when you say he has done this every other time, do you mean he has reported something like 12 consecutive quarters of double digit growth, made handfuls of accretive acquisitions and been profitable many quarters consecutively because that's exactly what he has done here.
While I disagree with you, I do appreciate you sharing your opinion. Never hurts to listen to others, regardless if you are not of the same opinion.
Thank you postyle, as always.
Noobie,
Still can't find anything on Dr. Andrews that would indicate he ever personally chose to serve on a public company's board of directors. Medovex appears to be the first and only.
You read about him? Check out who some of his patients have been.
A literal "whose who" of the sports world.
Andrews' list of patients include Carlos Beltran, C.C. Sabathia, Jamaal Charles, Tom Brady,[7]Albert Pujols, Matt Harvey, Michael Jordan, Jack Nicklaus, Emmitt Smith, John Smoltz, Troy Aikman, Ivan Nova, Josh Johnson, Charles Barkley, Roger Clemens, Drew Brees,[8] Reggie Bush, Andrei Markov, Bo Jackson, Adrian Peterson, Hope Solo, Marcus Lattimore, Robert Griffin III, Brett Favre, Ryan Broyles, Rajon Rondo, Mark Sanchez, Michael Morse, Jonny Venters, Nerlens Noel, Rickie Weeks, Sam Bradford, Braxton Miller, Dave Batista, Shawn Michaels, Triple H, John Cena, Edge, Randy Orton, CM Punk, Matt Moore,[9] Brian Cushing, Navorro Bowman, Kiko Alonso, James 'Jimmy Greek' Theofilos and Rob Gronkowski.[10]
It would appear as though Photobucket.coms settlement, being the first, has the potential of perhaps starting the chain of dominos so to speak. A potential catalysts that leads to subsequent settlements by other defendants. If I recall correctly, there were originally 18 named defendants?
What will be interesting is to see if there is any media coverage regarding the Markman hearing next week on the 20th.
I believe this the first time a Markman hearing has been set to take place at a college campus and incorporated into a class on patent law.
"October 16, 2014, Honorable United States District Judge T.S. Ellis, III, issued an order relating to all member cases in the TLI Communications LLC patent litigation."
"The order scheduled a claim construction hearing for 3:00 p.m., Tuesday, January 20, 2015, and the hearing will be held at the University of Virginia School of Law in Charlottesville, Virginia where it will be incorporated into a class on patent law."
He is using the fully diluted share count, yes. I believe they are at just about 13.6M shares outstanding and 19.5M or so fully diluted by my math.
hispeed,
Great info thank you. Any chance you would mind answering the same question I presented to Parkus? Would appreciate some insight into your thinking on what you believe a current fair value is, and what you're own personal price target is 12 months out.
Parkus,
I'm curious what you would consider an appropriate current valuation and do you have an expectation for 12 months out in terms of a price target?
Would value your thoughts.
Parkus,
That is a very good assessment in my opinion. Thanks for sharing it.
Like I said, to me it looks like they now have a more real, opportunistic, higher margin and scalable business than what they did when the stock last traded higher. Last time it moved up, they had virtually nothing that was actually tangible.
I have no clue what the stock does, if anything, but it's hard to not think the actual underlying fundamental value of the company should be higher today, than back then.
Stock didn't get here through continued success that is for sure.
That said I can only evaluate what has occurred recently. Like I said, is it perfection? Absolutely not, but it's hard to not consider it at least noteworthy progress.
Let's face it, many here just last week suggested there was no manual, or relationship with the Dr., Based on what we learned yesterday, it seems they were wrong on both accounts.
Again, it's where it is for a reason, but I see recent events as them finally living up to a promise. It's step in the right direction, that is all.
I don't think the point of the webinar was to impress because of what they were wearing or because of the setting. The point was to be real, promote transparency, educate, and answer questions. I'd suggest they did all of the above.
Like I said, credibility is not earned overnight, but this was another accomplishment that was promised and now full-filled.
It's a start.
Now we know that the Dr. is very real, very educated on the subject matter, and has a real relationship with the company and the manual is exclusive to Dutch. We now know they own a real asset and appear to have a real business plan. That's a lot more than many gave them credit for just last week if you recall.
While not suggesting everyone run out and buy the stock and it's clear much work needs to be done, truth is that this just may be the most opportunistic and truly scalable business the company has ever been involved with. Now the question is whether they can execute. We'll see, but recent events while they may not be perfection, they can only be considered progress.
Frankly, they appear to have a lot more going for them now, than when the stock last made a move higher into the .004 range.
I agree with you. I too have been here longer than most. We didn't get here because management got it right.
That said, in trying to be objective and not just talking my position, I can honestly say I'm pleasantly surprised by this webcast.
It solidifies a lot of what Hollis has been saying. You can't fake this. That's why I said you should be listening and watching it yourself.
Anyone who said the company didn't have the manual or a relationship with Dr. Michelle Reillo, has simply been proven wrong.
Like I said, it won't take much to move the needle on the stock if they keep slowly but surely earning back credibility. I see the webcast as a small step towards doing just that.
Just said the manual is exclusive to Dutch. People asked about that previously.
CBD education is a big market opportunity. Marketing to health care practitioners first according to Dr. Reillo. Lack of quality info available to health care practitioners. Consumer education opportunity also. Anyone aging, cronic pain etc. She's talking about the market for it as we speak.
Your prerogative, but this is incredibly informative and well done.
Can't predict it's effect on stock price, if any, but the company by all appearances has a business, a manual that can be sold and a heck of partner in Dr. Michelle Reillo.
One of the biggest myths is being dispelled as we speak. The company appears to have a real business and a real opportunity. Still work to be done but to me, this is another positive step in the right direction.
Not only did he remember, Dr. Michelle Reillo knows exactly who Dan Hollis is.
I hope some are watching this with their own eyes. Pretty educational to say the least.
I'm personally pretty blown away by not only this presentation but the depth on info I'm learning from it.
LOL!
I guess if it happens today, it could be considered the second thing he has lived up to recently. Step in the right direction albeit credibility is never restored overnight and often takes time.
In real dollars, the entire offer is just $12k. Not a lot of money in reality.
Let's see how the presentation goes today. Do you intend to listen in? I might not be able to so hopefully someone can give us their assessment.
I believe I recall him addressing that matter on the recent call myart8.
Only listened once but I do recall hearing him speak about it. My own understanding was that it was always only to be issued post becoming current on financials.
That has obviously unfortunately not happened yet. With limited financial resources, it doesn't surprise me. While I too would have liked to have received it, I guess it's better to have an actual product you can sell than to spend all the money on accountants absent a real business underlying it.
In the transcript, it list it as a question addressed.
http://www.authorstream.com/marcopolo2015/
DGRI CBD Sciences:
DGRI CBD Sciences Sustainable Business Model Doing Well by Doing Good
Where are we?:
Where are we? Capital efficient business model Mitigate regulatory impediments risk Crowd funding- no Banking- no MMJ-no, CBD yes Why does everything take so long Funding challenges Timing challenges Education site-site and webinar Consumer web store
Investor Questions:
Investor Questions Reasons for delay Reverse Stock Split- No Dilution-Yes Chill Removal Status Getting Current Dividend EPS growth Test Kits JV ABBA Balance Sheet improvement
Endocannabinoid System: The Missing Link:
Endocannabinoid System: The Missing Link Endocannabinoid System (ECS) is a lipid-derived signaling system discovered within past ten years Signals are conducted via circulating cannabinoids which are homeostatic regulators affecting all physiological systems Cannabinoids attach to CB1 and CB2 receptors throughout the body CB1 receptors are excitatory and are located in the central nervous system, lungs, liver, and kidney CB2 receptors are located in the immune and circulatory systems
Clinical Endocannabinoid Deficiency:
Clinical Endocannabinoid Deficiency Clinical Endocannabinoid Deficiency (CECD) associated with Disorders and Diseases Decreased circulating endocannabinoids reduce signaling causing physiological dysfunction CB1 and CB2 receptors decline with CECD CECD can be Genetic, Acquired, or Idiopathic Autoimmune Examples: Genetic: Alzheimer’s Acquired: Chronic Traumatic Encephalopathy (CTE) Idiopathic Autoimmune: Multiple Sclerosis
Education is the KEY:
Education is the KEY Health Care Professionals Regulators General public Disease Association & Support Groups Special Interest Groups NFL, NHL, NCAA University Research Facilities Specialty health care providers
Health Care Education:
Health Care Education Continuing Medical Education Symposia Certifications Medical Conferences
Regulators:
Regulators State legislative outreach Educational website- legislators only Expert testimony panel Manual given to Chief Medical Officer each state, and each state Governor, etc
General Population:
General Population Website Social networking Community building E-book launches Radio TV
Recurring Revenue Models:
Recurring Revenue Models Medical Education Patient Education Cohort Communities Supplements Disease state management
Health Care Professional Outreach:
Health Care Professional Outreach CME Courses Professional Journals White papers Outreach to specialist organizations Product launches directed to healthcare providers- Immunosupport
Delivery Mechanisms:
Delivery Mechanisms Capsules Dissolving oral strips Beverages Topical ointments/gels Trans-dermal patches
Launch Plan :
Launch Plan Publish Medical CBD Manual Begin CME courses Launch Cohort Community Sites Specialized outreach Athletes Cancer Survivor Release E-book- CTE & Concussions Launch Nutraceutical Formula Neuro-Cognitive
Launch Plan Continued:
Launch Plan Continued Release 4 E-books 2015- one per quarter Release matching specialty CBD formula each quarter Certify Physician experts in 20 major SMA’s Attract patients to Certified Clinics Provide tracking data for each patient
Chronic Traumatic Encephalopathy:
Chronic Traumatic Encephalopathy NFL- $750M settlement NCAA- $50M lawsuit High School- 4 deaths this school year General population- 50M untreated concussion
Intellectual Property:
Intellectual Property Manuals CME courses E-books Medical protocols Nutraceutical formulations New strains of industrial hemp
Joint Ventures:
Joint Ventures ABBA Medix Canada Mid East Professional Sports-in discussion Collegiate Sport- in discussion
Foundation for Growth:
Foundation for Growth Intellectual Property Education Physicians Consumers Nutraceutical Formulations Distribution Network Physician based Consumer based Association based
Mick,
The manual appears to be exclusive to Dutch based on the executed contract here:
http://dutchgoldinc.com/material-contracts
Appears as though what the other company was referencing and what Dutch has are different. Again, someone should confirm it on next weeks call, but it appears self evident based on the contract.
We've all been at the height of frustration and disappointment moneybags. We are talking about a .001 penny stock that didn't get here by management fulfilling our collective expectations. I don't even want to think about how much this stock cost me.
Next weeks call should give us some better understanding of the potential opportunity and answer any questions posed earlier. Not ready to celebrate yet, but it appears to be a step in the right direction. We shall see...
I believe the manual is exclusive to Dutch and what's referenced there is not one and the same. The release states "to write a series of manuals". Nevertheless, I have a call into the company to get an answer and will report back to you if I hear back.
I believe Lexaria is a company that sells Tea's? You can obviously call them and do the same if you like. Better, I'm sure it would be a great question to ask at next weeks presentation announced yesterday.
It would appear to be her djsunfield.
http://www.academia.edu/4380508/The_Lived_Experience_of_HTV7AIDS_A_Heideggerian_Hermeneutical_Analysis
PhD, Notre Dame University Education and Also Received my Masters Degree in Geriontology. I am a Recipient of The Albert Schweitzer Fellowship at Johns Hopkins
Expertise:
hyperbaric medicine. I am trained in the fields of critical care and infectious disease at the University of Maryland, have been involved in the treatment of patients with AIDS since the beginning of the epidemic in 1983. As a pioneer in the field, I have been principal investigator on several AIDS research studies and developed clinical protocols for health practitioners in the management of patients with HIV/AIDS. I've written numerous articles which were published in peer reviewed medical and nursing journals. My inspiration to work with HIV/AIDS patients was due to the loss of a dear friend. I am the author of AIDS Under Pressure, (Hogrefe & Huber, 1997)
Hobbies:
bicycling, music, art and spending time with family and my dogs
About Michelle
I was born and educated in Baltimore, Maryland, receiving my undergraduate degree at the University of Maryland and my Doctorate at the College of Notre Dame. I completed my Albert Schweitzer Fellowship at John Hopkins and have been fortunate to have had the opportunity to author a book, AIDS Under Pressure, as well as multiple journal and professional articles. My career has been greatly influenced by the HIV/AIDS pandemic and I pioneered the application of hyperbaric medicine in HIV/AIDS to enhance the quality of life of individuals infected with HIV. As a director of a hyperbaric medical facility and university educator, I have had the experience of both teaching and research. My work in hyperbaric medicine and immunology has branched outwardly in various directions, including the veterinarian fields and the athletic arenas. My recent research projects and clinical applications include sports and hyperbaric medicine, which has recently been published in the Sports Journal and Sports Digest, featuring original work in dance and the performing arts. I believe that art and medicine are congruent partners in practice and that creativity is paramount in life. Research is key to marketing and ideas for exploration exist within our personal life experiences and visions. Intuition and a willingness to think outside the box, combined with a conscious awareness of the human experience, enhance professional and business directions. Authenticity is a dance of learning the art of being an empathetic human; tangibly molding the clay is what makes us real.
Thank you for the correction Crusher. A simple Google search would have immediately identified her as a Dr.
Neither here nor there, since you surely would have found and posted anything even remotely negative, I must assume you too have found the Dr. to be in good standing and fairly well regarded just as I did?
pittski,
I understand your skepticism and rightfully so.
I'm merely pointing out that some may have been erroneous based on recent comments. The manual exists.
I'm indifferent whether you do any dd or not. I can only speak for myself and generally speaking, I refrain from having opinions unless properly educated. If you change your mind on looking further, I might simply suggest you consider listening to next weeks webcast where she will be speaking about it. Surely she will confirm the relationship I'd have to assume.
Again, from what I can find, this is a well regarded Dr. who knows this space well. I can't answer why she partnered with Dutch on the project, but it appears she clearly has. Based on what I have read, she strikes me as pretty intelligent and educated. Not the type I would expect to enter into any business dealings haphazardly. If you or anyone finds anything to the contrary, by all means please let me know along with the others.
moneybags,
Good news my friend. A little cautious optimism just may be in order. Down, but perhaps not out.
Management appears to have kept their word doing exactly as they stated they would. While maybe not yet a pattern, it's hard to not consider this a BIG step in the right direction. This is the type of tangible evidence of real progress that I've been demanding. One could argue it confirms the presence of a real business being built, despite the recent stock prices indication to the contrary.
The manual appears not only very real, but its author Dr. Reillo seems to be pretty well regarded in her own right. Google here.
The following press release issued in the last few minutes.
The Cannabinoid Manual Publishing Rollout Begins
Meet the Author, Dr. Michelle Reillo in a Live Webinar
ATLANTA, GA, Jan 08, 2015 (Marketwired via COMTEX) -- Dutch Gold Resources, Inc. (OTC PINK: DGRI) (the "Company") (dutchgoldinc.com) today announced that its subsidiary, Ascendant Therapeutics, Inc., has completed the initial draft of its new book, The Cannabinoid Manual, by Dr. Michelle Reillo. The Company will host a webinar on Tuesday, January 13, 2015 at 2PM EST, to introduce Dr. Reillo, where she will discuss the development of the manual and how health care professionals and consumers might use the book.
The Manual is based on over 1,500 peer reviewed scientific papers and presents leading edge information on the impact of Cannabidiol on health and healing. Covering more than two-dozen diseases, the manual discusses the effect of Cannabidiol supplementation on the endocannabinoid system in the human body. Over 1,100,000 people use medical marijuana every month many without a clear understanding of cannabinoids. (Source medicalmarijuana.procon.org/view.resource.php?resourceID=005889). The Company believes that the market for CBD products exceeds 15,000,000 prospects. This manual represents the first true compilation of the scientific data generated over the last twenty years, up to now.
Said Dr. Reillo, "The Cannabinoid Manual illuminates the newly discovered endocannabinoid system as the central physiological conductor of homeostasis. The exploration of how cannabinoid receptors and phytocannabinoids interact in disease processes and the possibilities for prevention and medical management of disorders utilizing adjunctive Cannabidiol (CBD ) from legal industrial hemp is critical for all health care practitioners, including physicians, nurse practitioners, nurses, chiropractors, and dentists."
The webinar event may be accessed by registering at http://webinarjam.net/webinar/go/13700/27e47b98b0. This webinar focuses on the potential uses of CBD and health and is appropriate for both healthcare professionals and consumers. Interested investors are urged to attend, as an update on the publishing of the manual will be discussed as well as other corporate developments. We encourage everyone to attend. Our goal is to bring this important information to as many people as possible, to help improve the health of any many as possible.
Forward-Looking Statements
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Dutch Gold Resources, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
For further information, please see www.DutchGoldInc.com or please contact
Daniel Hollis
CEO of Dutch Gold Resources, Inc.
404-981-7424
SOURCE: Dutch Gold Resources
(C) 2015 Marketwire L.P. All rights reserved.